NATICK, Mass., March 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the Society for Cardiovascular Angiography and Interventions SCAI Annual Scientific Sessions in Partnership with the American College of Cardiology ACC/i2 Summit, which runs from March 29 to April 1 in Chicago.
"Clinical data presented at ACC for the TAXUS(R) paclitaxel-eluting
coronary stent will report on outcomes in a variety of high-risk patient
populations," said Paul LaViolette, Chief Operating Officer of Boston
Scientific. "We expect results will show continued positive data for the
TAXUS Stents in these complex patients and lesions."
Schedule of Events (all times are Central Time)
Saturday, March 29
-- ARRIVE Diabetic Analysis. D. Lynn Morris, M.D., will present one-year
outcomes from a pooled analysis of the ARRIVE 1 & 2 Registries,
including subset data for 4,772 patients, including 1,530 diabetics.
The ARRIVE program is designed to collect and analyze "real-world"
safety and clinical outcomes data for the TAXUS(R) Express2(TM)
paclitaxel-eluting stent system in the treatment of patients with
coronary artery disease. The diabetic sub-group analysis is designed
to evaluate clinical restenosis in diabetic patients and non-diabetics
treated with the TAXUS Express2 Stent. The results will be presented
at 8:00 a.m., during an e-poster session. The Company plans to issue a
press release at this time.
-- ARRIVE High-Risk Patient Analysis. John M. Lasala, M.D., will present
two-year data from 7,307 high-risk patients in t
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved